Circulogene Launches AI Blood Test for Lung Nodule Assessment

Circulogene has announced the exclusive commercial launch of LungLifeAI, an AI-driven blood-based test designed to aid in the clinical decision-making process for patients with indeterminate pulmonary nodules (IPNs) detected via CT scans, announced in a press release. This innovative test aims to improve the accuracy of malignancy assessments, particularly for nodules smaller than 2 cm, by providing high-performance molecular biomarker analysis.

LungLifeAI offers an 80% Positive Predictive Value (PPV), 77% sensitivity, and 74% specificity, enabling earlier and more accurate assessments of potential malignancies. The test utilizes advanced AI to analyze chromosomal signal patterns in thousands of cells, providing deep molecular insights into nodule behavior and risk.

The test is designed to streamline the diagnostic process with a simple blood collection kit, which includes mobile phlebotomy options. This approach supports physicians in determining which small nodules require biopsy, facilitating timely treatment plans. Mike Mullen, CEO of Circulogene, emphasized the test's role in complementing their existing OncoGenLDx tumor profiling test by offering actionable insights when CT imaging alone is insufficient.